# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst John Newman maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $2...
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...
Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0...
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., Apr...
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confid...
Alliance Global Partners analyst James Molloy maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target...
HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...